Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis.

BMC cancer - 14 Jun 2022

Gen Soei, Tanaka Ichidai, Morise Masahiro, Koyama Junji, Kodama Yuta, Matsui Akira, Miyazawa Ayako, Hase Tetsunari, Hibino Yoshitaka, Yokoyama Toshihiko, Kimura Tomoki, Yoshida Norio, Sato Mitsuo, Hashimoto Naozumi

Abstract excerpt

BACKGROUND: Osimertinib-the third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)-has been widely used as a first-line treatment for patients with metastatic EGFR-mutant non-small cell lung cancer (NSCLC). Osimertinib demonstrated central nervous system activity in patients with brain metastasis; however, its efficacy against other distant metastatic organs, including bone and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Indoles

Share to Liver Neoplasms

Share to Neoplasm Metastasis

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 35698083
DOI: 10.1186/s12885-022-09741-8
PMCID: PMC9195197

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis.PMID 35698083Read ↗

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasisSemantic proximity Read ↗

Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies.Semantic proximity Read ↗

Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: Osimertinib vs. first-generation EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

Osimertinib for EGFR-mutant lung cancer with central nervous system metastases: a meta-analysis and systematic review.Semantic proximity Read ↗

Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer.Semantic proximity Read ↗

Osimertinib combined with bevacizumab as the first-line treatment in non-small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations.Semantic proximity Read ↗

Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR-mutant nonsmall cell lung cancer with brain metastasis.Semantic proximity Read ↗

A comprehensive prognostic analysis of osimertinib treatment in advanced non-small cell lung cancer patients with acquired EGFR-T790M mutation: a real-world study.Semantic proximity Read ↗

Efficacy of 3rd generation TKI in patients with EGFR mutation lung adenocarcinoma with bone metastases: A review of 3 case reports and literature.Semantic proximity Read ↗

Osimertinib versus afatinib in patients with T790M-positive, non-small-cell lung cancer and multiple central nervous system metastases after failure of initial EGFR-TKI treatment.Semantic proximity Read ↗

Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Osimertinib readministration for central nervous system metastases in non–small cell lung cancer positive for EGFR activating mutationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.